Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

被引：90

作者：

Ribas, Antoni

Robert, Caroline

Hodi, F. Stephen

Wolchok, Jedd D.

Joshua, Anthony M.

Hwu, Wen-Jen

Weber, Jeffrey S.

Zarour, Hassane M.

Kefford, Richard

Loboda, Andrey

Albright, Andrew

Kang, Soonmo Peter

Ebbinghaus, Scot

Yearley, Jennifer

Murphy, Erin

Nebozhyn, Michael

Lunceford, Jared K.

McClanahan, Terri

Ayers, Mark

Daud, Adil

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Gustave Roussy, Villejuif, France

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[8] Univ Pittsburgh, Pittsburgh, PA USA

[9] Macquarie Univ, Sydney, NSW 2109, Australia

[10] Westmead Hosp, Sydney, NSW, Australia

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] UC San Francisco, San Francisco, CA USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.3001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

3001

引用

页数：1